Sorriso Pharmaceuticals Reports Positive Phase 1b Results for SOR102 in Ulcerative Colitis
Sorriso Pharmaceuticals, a biopharmaceutical company focused on developing novel oral antibodies for immune-mediated diseases, today announced positive results from its Phase 1b clinical trial of SOR102. This oral, dual-acting biologic targets TNFα and IL-23 and was tested in patients with…
Uno Health Launches Free Tool for Vulnerable Americans Amid Rising Costs
Uno Health, a service aimed at increasing access to benefits and savings for lower-income Americans, has launched the Uno Savings Guide. This free tool helps individuals of all ages, including Medicare and Medicaid recipients, by determining eligibility for financial benefit…
FlexIt Launches FlexTogether™, Revolutionizing Fitness and Global Connectivity
FlexIt, a leader in virtual fitness and wellness, is excited to announce the launch of FlexTogether™, a groundbreaking platform designed to connect individuals globally through innovative wellness experiences. This new initiative features FlexIt’s proprietary AI Class Creator™ Technology, which enhances…
Jacques Gilbert Named Chief Strategy and Business Development Officer at Topcon Healthcare
Topcon Healthcare, Inc., a leading provider of medical devices and digital healthcare solutions, is excited to announce the appointment of Jacques Gilbert as Chief Strategy and Business Development Officer. In this key role, Jacques will spearhead the development and execution…
LimmaTech’s Staphylococcus aureus Vaccine Candidate Gets FDA Fast Track Status
LimmaTech Biologics AG, a clinical-stage biotech company focused on developing vaccines for life-threatening diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its multivalent toxoid vaccine candidate, LBT-SA7. The vaccine is designed…
Vivani Medical Launches First Human Trial of GLP-1 Implant for Obesity in Australia
Vivani Medical, Inc. (Nasdaq: VANI), an innovative biopharmaceutical company specializing in novel, ultra long-acting drug implants, today announced the initiation of screening and enrollment for its first-in-human clinical trial, LIBERATE-1™, at two centers in Australia. The trial aims to evaluate…
Axoft Launches Brain Implant Clinical Study with First Bio-Inspired Material for Humans
Axoft, a neurotechnology company, has announced the approval of its first-in-human clinical study, set to begin in early 2025 at The Panama Clinic. The study will explore the usability of Axoft’s innovative soft materials, which mimic the mechanical properties of…
SV Health Investors Elevates A.J. Rossi to Partner on Healthcare Team
SV Health Investors, a prominent healthcare-focused private equity firm, is excited to announce the promotion of A.J. Rossi to Partner on its Growth-Buyout team. In this role, A.J. will continue to lead investments, oversee the SV portfolio, and contribute to…
COTA and Guardant Health Partner to Advance Precision Oncology with AI and Real-World Data
COTA Inc., a leader in real-world data (RWD) and analytics for oncology, has announced a new partnership with precision oncology company Guardant Health Inc. (Nasdaq: GH). This collaboration will provide biopharmaceutical researchers with access to COTA’s research-grade electronic health record…
Palleon Pharmaceuticals and Henlius Collaborate on Glycan Editing for Autoimmune Diseases
Palleon Pharmaceuticals, a leader in glyco-immunology drug development for autoimmune diseases and cancer, has announced a collaboration and licensing agreement with Shanghai Henlius Biotech, Inc. (2696.HK). The agreement focuses on the development and commercialization of Palleon’s novel human sialidase enzyme…
Insitro Secures $25 Million from Bristol Myers Squibb for ALS Target Discovery Milestones
Insitro, a machine learning-driven drug discovery and development company, announced today that it has received $25 million from Bristol Myers Squibb (NYSE: BMY) following the achievement of discovery milestones and the selection of the first novel genetic target for amyotrophic…
Valink Therapeutics Appoints Martin D. Williams as Board Chair, Names Scientific Advisory Board
Valink Therapeutics, a biopharmaceutical company focused on the discovery and development of bispecific antibody-drug conjugates (bsADCs) to treat cancer and other diseases, has announced the appointment of Martin D. Williams as Chair of its Board of Directors. Additionally, the company…